Erratum

In March/April 2017, the Journal of the Brazilian College of Surgeons [Rev Col Bras Cir. 2017;44(2):179-86] published the original article titled "Immediate reconstruction with autologous fat grafting: influence in breast cancerregional recurrence." (http://dx.doi.org/10.1590/0100-69912017002012), by Camile Cesa Stumpf; Jorge Villanova Biazus; Fernando Schuh Ângela Erguy Zucatto; Rodrigo Cericatto; José Antônio Crespo Cavalheiro; Andrea Pires Souto Damin; Márcia Portela Melo. The following errors were identified:

Title:

Reads:
"…influence in breast cancerregional recurrence";
Should read:
"…influence in loco regional recurrence in breast cancer.

Tables:

Reads:
Table 1. *Clinical and histological characteristics of the patients with invasive ductal carcinoma who underwent either conservative surgery with lipofilling or only conservative surgery.*

	BCS* + Lipofilling (n=27)	BCS (n=167)
Age (mean in years)	53.6 ± 10.9	56.4 ± 12.0
Tumor size (mm)	24.3 ± 10.5	20.6 ± 12.0
Histological grading		
I	7 (25.9)	38 (22.8)
II	9 (33.3)	85 (50.9)
III	11 (40.7)	44 (26.3)
Clinical staging (TNM)		
I	7 (25.9)	78 (46.7)
II	20 (74.1)	89 (53.3)
Histology		
IDC	24 (88.9)	149 (89.2)
ILC	3 (11.1)	18 (10.8)
Estrogen receptor		
Present	22 (81.5)	128 (76.6)
Absent	5 (18.5)	39 (23.4)
Progesterone receptor		
Present	22 (81.5)	116 (69.5)
Absent	5 (18.5)	51 (30.5)
HER2		
Overexpressed	3 (11.1)	19 (11.4)
Not overexpressed	20 (74.1)	137 (82.0)
Undertermined	4 (14.8)	11 (6.6)
Neoadjuvant chemotherapy	1 (3.7)	26 (15.6)
Adjuvant chemotherapy	17 (63.0)	62 (37.1)
Adjuvant radiotherapy	27 (100)	163 (97.3)
Time to start of adjuvant therapy (months)	1 (1-2)	2 (1-4)

Categorical variables described as n (%); Symmetric quantitative variables described as means ± standard deviation; Asymmetric quantitative variables described as means (P25-P75); BCS- Breast Conservative Surgery; IDC- invasive ductal carcinoma; ILC- invasive lobular carcinoma.

Should read:

Table 1. *Clinical and histological characteristics of the patients with invasive ductal carcinoma who underwent either conservative surgery with lipofilling or only conservative surgery.*

	BCS* + Lipofilling (n=27)	BCS (n=167)	p
Age (mean in years)	53.6 ± 10.9	56.4 ± 12.0	0.268
Tumor size (mm)	24.3 ± 10.5	20.6 ± 12.0	0.134
Histological grading			0.194
I	7 (25.9)	38 (22.8)	
II	9 (33.3)	85 (50.9)	
III	11 (40.7)	44 (26.3)	
Clinical staging (TNM)			0.070
I	7 (25.9)	78 (46.7)	
II	20 (74.1)	89 (53.3)	
Histology			1.000
IDC**	24 (88.9)	149 (89.2)	
ILC***	3 (11.1)	18 (10.8)	
Estrogen receptor			0.757
Present	22 (81.5)	128 (76.6)	
Absent	5 (18.5)	39 (23.4)	
Progesterone receptor			0.294
Present	22 (81.5)	116 (69.5)	
Absent	5 (18.5)	51 (30.5)	
HER2			0.330
Overexpressed	3 (11.1)	19 (11.4)	
Not overexpressed	20 (74.1)	137 (82.0)	
Undertermined	4 (14.8)	11 (6.6)	
Neoadjuvant chemotherapy	1 (3.7)	26 (15.6)	0.135
Adjuvant chemotherapy	17 (63.0)	62 (37.1)	0.020
Adjuvant radiotherapy	27 (100)	163 (97.3)	1.000
Time to start of adjuvant therapy (months)	1 (1-2)	2 (1-4)	0.041

Categorical variables described as n (%); Symmetric quantitative variables described as means ± standard deviation; Asymmetric quantitative variables described as means (P25-P75); *BCS- Breast Conservative Surgery; **IDC- invasive ductal carcinoma; ***ILC- invasive lobular carcinoma.

Reads:

Table 2. *Recurrence in the lipofilling and breast conservative surgery groups.*

	BCS* + Lipofilling (n=27)	BCS (n=167)
Overall recurrence	1 (3.7)	7 (4.2)
Local recurrence		
Yes	7 (25.9)	38 (22.8)
No	9 (33.3)	85 (50.9)
Systemic recurrence		
Yes	7 (25.9)	78 (46.7)
No	20 (74.1)	89 (53.3)

Categorical variables described as n (%); *BCS- Breast Conservative Surgery.

Should read:

Table 2. *Recurrence in the lipofilling and breast conservative surgery groups.*

	BCS* + Lipofilling (n=27)	BCS (n=167)	p
Overall recurrence	1 (3.7)	7 (4.2)	1.000
Local recurrence			1.000
Yes	0 (0.0)	4 (2.4)	
No	27 (100)	163 (95.8)	
Systemic recurrence			0.454
Yes	1 (3.7)	3 (1.8)	
No	26 (96.3)	164 (98.2)	

Categorical variables described as n (%); *BCS- Breast Conservative Surgery.